Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
Jaguar Health shares rose 9.2% to $3.67 Wednesday after first-quarter revenue jumped to $20.3 million, mainly from a U.S. licensing deal for Mytesi and Canalevia-CA1. Trading volume surged to 593,152 shares. Net loss narrowed to $7.0 million from $10.5 million a year earlier. The company’s crofelemer rare-disease trial advanced with its first pediatric patient entering an extension phase.